-
Sector Analysis
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the...
-
Sector Analysis
Hypoglycemia Drug Market Size, Company Share, Trends Analysis and Forecast 2021-2030
The hypoglycemia drug sales have been valued to $423.5 million across the 7MM in 2020 growing at a CAGR of more than 4%. The US has contributed more than 90% of the sales that is primarily due to the significantly higher prices of glucagons in the US, a relatively high diagnosed prevalence of type 1 diabetes (T1D) and high incidence rate of post-bariatric hypoglycemia (PBH). The next largest individual markets are Italy and Germany. Therefore, altogether the 5EU countries make...
-
Sector Analysis
Growth Hormone Deficiency (GHD) - Opportunity Assessment and Forecast
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany and Japan. These therapies are projected to capture over 90% of market share in this region by 2030 due to their potential to improve patient convenience and compliance. Usage of short-acting GHs will markedly decrease over the forecast period as almost all patients switch to treatment with long-acting GHs. These therapies only require...
-
Sector Analysis
Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). This GH excess is often a result of a benign GH-secreting pituitary adenoma. Rarely, tumors in other organs can secrete growth hormone-releasing hormone (GHRH), leading to elevation in GH levels in the serum. This triggers the release of anti-apoptotic and mitogenic peptide hormone, insulin-like growth factor 1 (IGF-1). While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentation of...
-
Sector Analysis
Fabry Disease - Opportunity Assessment and Forecast
Fabry Disease, or FD for short, refers to a rare, inherited X-linked lysosomal storage disease (LSD) whereby mutations in the galactosidase-α (GLA) gene encoding the lysosomal enzyme α-GAL A. Due to a deficiency or absence of GLA, an enzyme substrate, primarily globotriaosylceramide (Gb3) accumulates throughout the blood vessels, other tissues, and organ. Clinical manifestations include, but are not limited to, renal, cardiac and cerebrovascular complications, as well as pain, angiokeratoma, gastrointestinal disturbance, an overall reduce quality of life and early...
-
Sector Analysis
Pompe Disease - Opportunity Assessment and Forecast to 2030
This report covers 3MM (US, Germany and Japan) and provides an Excel-based forecast model for the Pompe Disease market through 2030.
-
Sector Analysis
Diabetic Retinopathy - Global Drug Forecast and Market Analysis to 2029
Diabetic retinopathy (DR) is a sight-threatening, prevalent complication of type 1 and 2 diabetes which is characterized by damage to the small blood vessels in the retina. As the most common microvascular complication of diabetes, more than 60% of patients will experience DR within 20 years of developing diabetes. DR the principal cause of preventable vision loss in working-age adults around the world. There are two major clinical stages of diabetic retinopathy: a less severe subtype known as non-proliferative diabetic...
-
Sector Analysis
Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029
Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis...
-
Sector Analysis
PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2025
GlobalData estimates sales of dyslipidemia therapeutics to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in...
-
Sector Analysis
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026
While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians’ efforts to delay disease progression and reduce the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.